Future investigations will be focused on the mechanism of the activated TLR3 in inhibiting HCC, and ultimately, a more effective anti-HCC therapy will be evaluated using a combination use of sorafenib and dsRNA. This evidence concerns the gene TLR3 and hepatocellular carcinoma.